Destiny Wealth Partners’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Destiny Wealth Partners’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22K	Buy	+270	New	+$22.4K	﹤0.01%	643
2023 Q1	–	Sell	-270	Closed	-$15.6K	–	229
2022 Q4	$15.6K	Hold	270	–	–	﹤0.01%	432
2022 Q3	$13K	Hold	270	–	–	﹤0.01%	398
2022 Q2	$13K	Hold	270	–	–	﹤0.01%	400
2022 Q1	$17K	Hold	270	–	–	﹤0.01%	395
2021 Q4	$22K	Hold	270	–	–	﹤0.01%	382
2021 Q3	$26K	Buy	+270	New	+$27.3K	0.01%	354
2021 Q2	–	Sell	-270	Closed	-$23K	–	214
2021 Q1	$23K	Hold	270	–	–	﹤0.01%	349
2020 Q4	$23K	Buy	+270	New	+$20.9K	﹤0.01%	348

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

KFS

Kaizen Financial Strategies Campbell, California $236M AUM 28.3% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Destiny Wealth Partners's BIB Position: Q1 2026 in Review

Destiny Wealth Partners opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026: 270 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #643 among its holdings. This is a return to the name: Destiny Wealth Partners previously reported a position in BIB as recently as Q4 2022.

Destiny Wealth Partners first reported a position in BIB in Q4 2020 and has held it in 9 quarters since. The position peaked at $26K in Q3 2021. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

Destiny Wealth Partners held 270 shares of ProShares Ultra NASDAQ Biotechnology worth $22K as of Q1 2026.
ProShares Ultra NASDAQ Biotechnology was a new Destiny Wealth Partners position in Q1 2026.
ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Destiny Wealth Partners's portfolio in Q1 2026, its #643 holding.
Destiny Wealth Partners first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2020 and has held it in 9 quarters since.
Destiny Wealth Partners's ProShares Ultra NASDAQ Biotechnology position peaked at $26K in Q3 2021.
23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Destiny Wealth Partners's 13F filing for Q1 2026, filed 11 May 2026.